论文部分内容阅读
亚洲厂商低成本产品的介入和产能过剩使最近一、两年抗生素中间体 /原料药价格疲软。随着亚洲厂商市场份额不断增加 ,这一趋势还将继续。中国盘尼西林消费量占全球总消费量的 1/3 ,且对头孢菌素的需求将大幅增加 ,这必然会带动全球抗生素中间体的消费。目前头孢菌素原料药需求量年增长率为 12 %～ 15 %。各大抗生素中间体厂商纷纷关停效益差的小装置 ,并依靠酶和发酵等新技术来降低生产成本、增加利润。另外引人注目的是GSK公司的克拉维酸钾 /三水合阿莫西林 ,2 0 0 2年该药的全球销售额达 2 2亿美元
Asian manufacturers low-cost product intervention and overcapacity last year, two antibiotic intermediates / API prices weakness. With the increasing market share of Asian manufacturers, this trend will continue. China’s consumption of penicillin accounts for one-third of the global total consumption, and the demand for cephalosporins will increase substantially, which will inevitably lead to the consumption of antibiotic intermediates around the world. The current annual demand for cephalosporin API growth rate of 12% to 15%. Major antibiotic intermediates manufacturers have shut down the poor efficiency of small devices, and rely on enzymes and fermentation and other new technologies to reduce production costs and increase profits. Also of note is GSK’s clavulanate potassium / amoxicillin trihydrate, which has global sales of 2,200 million dollars in 2002